Insys Therapeutics (INSY) Earns Hold Rating from Oppenheimer

Insys Therapeutics (NASDAQ:INSY)‘s stock had its “hold” rating reissued by stock analysts at Oppenheimer in a research note issued to investors on Sunday, November 12th.

Other equities analysts have also issued research reports about the company. BidaskClub upgraded Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 26th. Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada dropped their price target on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, TheStreet lowered Insys Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, August 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $9.38.

Insys Therapeutics (INSY) traded down $0.05 on Friday, reaching $5.25. The company’s stock had a trading volume of 385,976 shares, compared to its average volume of 764,310. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.

Several hedge funds have recently modified their holdings of INSY. KCG Holdings Inc. lifted its holdings in Insys Therapeutics by 42.0% in the first quarter. KCG Holdings Inc. now owns 26,160 shares of the specialty pharmaceutical company’s stock valued at $275,000 after acquiring an additional 7,735 shares during the period. Schneider Capital Management Corp raised its stake in shares of Insys Therapeutics by 100.0% during the 2nd quarter. Schneider Capital Management Corp now owns 119,973 shares of the specialty pharmaceutical company’s stock worth $1,518,000 after buying an additional 60,000 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Insys Therapeutics by 37.9% during the 1st quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock worth $480,000 after buying an additional 12,561 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of Insys Therapeutics during the 2nd quarter worth approximately $612,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Insys Therapeutics during the 1st quarter worth approximately $172,000. Institutional investors and hedge funds own 25.65% of the company’s stock.

WARNING: This article was first posted by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/insys-therapeutics-inc-insy-given-hold-rating-at-oppenheimer-holdings-inc/1779388.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.